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The liver fluke Opisthorchis viverrini is a food-borne, zoonotic pathogen endemic to 
Thailand and adjacent countries in Southeast Asia. The adult developmental stage 
of the O. viverrini parasite excretes and secretes numerous proteins within the biliary 
tract including the gall bladder. Lesions caused by the feeding activities of the liver fluke 
represent wounds that undergo protracted cycles of healing and re-injury during chronic 
infection, which can last for decades. Components of the excretory/secretory (ES) 
complement released by the worms capably drive proliferation of bile duct epithelial cells 
and are implicated in establishing the oncogenic milieu that leads to bile duct cancer, 
cholangiocarcinoma. An ES protein, the secreted granulin-like growth factor termed Ov-
GRN-1, accelerates wound resolution in mice and in vitro. To investigate angiogenesis 
(blood vessel development) that may contribute to wound healing promoted by liver 
fluke granulin and, by implication, to carcinogenesis during chronic opisthorchiasis, we 
employed an in vitro tubule formation assay (TFA) where human umbilical vein endothelial 
cells were grown on gelled basement matrix. Ten and 40 nM Ov-GRN-1 significantly 
stimulated angiogenesis as monitored by cellular proliferation and by TFA in real time. 
This demonstration of potent angiogenic property of Ov-GRN-1 bolsters earlier reports 
on the therapeutic potential for chronic non-healing wounds of diabetics, tobacco users, 
and the elderly and, in addition, showcases another of the hallmark of cancer character-
istic of this carcinogenic liver fluke.
Keywords: granulin, parasite, angiogenesis, wound healing, liver cancer, human umbilical vein endothelial cells, 
tubule formation assay
inTrODUcTiOn
Infection with the fish-borne liver flukes Opisthorchis viverrini, Opisthorchis felineus, and Clonorchis 
sinensis remains a major public health problem in East Asia and Eurasia with >40 million cases. O. 
viverrini is endemic in regions of Thailand, Cambodia, Lao PDR, and Vietnam (1), and opisthorchia-
sis has been extensively studied in Thailand where ~8 million people are infected, calculated from 
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nation-wide prevalence of 9.4% for the Thai population in 2001 
(2, 3). Eating undercooked fish infected with the metacercariae 
stage of the fluke leads to infection in humans and other mam-
mals, such as cats and dogs (1). The metacercarial stage of the 
parasite excysts in the duodenum and the juvenile fluke migrates 
into the bile ducts of the liver and matures over a month into an 
adult fluke, which grazes on biliary epithelia. The parasites are 
long lived, and often persist in the biliary tree for decades (1, 3). 
Fluke eggs are shed into the bile and exit with the fecal stream 
(1). Eggs that enter fresh water ecosystems can be ingested by the 
gastropod snail Bithynia siamensis (2, 4). The parasite develops 
within the snail, in turn releasing cercariae that seek out and 
penetrate the skin of a cyprinid fish, which encyst in the fish as a 
metacercaria, the infective stage for humans and other definitive 
host species (1).
Infection causes hepatobiliary disease, including cholangitis 
and periductal fibrosis (1). More problematically, both experi-
mental and epidemiological evidence strongly implicates liver 
fluke infection in the etiology of cholangiocarcinoma (CCA), 
commonly known as bile duct cancer—one of the major liver 
cancer subtypes (1, 5). Up to 81% of liver cancers in the endemic 
Isaan region in north-eastern Thailand are CCA, which also 
suffers the world’s highest incidence of CCA—65 times the 
rate experienced in non-endemic regions (1, 5, 6). CCA is an 
adenocarcinoma that generally exhibits slow growth and which is 
diagnosed at advanced stage often with metastasis to distant sites 
due to proximity to lymphatic vessels (4). Unfortunately, prog-
nosis is dismal at the advanced stage when the primary tumor 
is no longer amenable to liver resection. The mechanism(s) by 
which infection initiates genetic lesions that eventually culminate 
in CCA is unclear, but it likely involves biliary tract and systemic 
inflammation, inflammation associated endogenous and dietary 
nitrosation, and secretion of mitogens and other by the liver fluke.
One aspect of liver fluke infection that is potentially involved 
in malignant transformation is the excessive, unremitting wound 
healing in response to continued feeding by the parasites on 
bile duct tissue (2, 3, 5). We have shown that the granulin-like 
growth factor, Ov-GRN-1, secreted by the fluke is the dominant 
proliferative factor and is sufficient to drive wound healing (2, 7). 
A critical step in new tissue generation, including wound healing 
and tumor growth induced by the infection, is the stimulation 
of angiogenesis—the formation of new capillaries from pre-
existing blood vessels or vasculogenic stem cells (8). New tissue 
requires angiogenesis to supply oxygen and nutrients, facilitate 
immune surveillance, and remove waste products (9). A complex 
interplay of growth factors and inhibitors regulates angiogenesis 
and imbalance can lead to disease (10). While angiogenesis does 
not itself initiate malignancy, it can promote tumor progression 
and metastasis (9, 11). Angiogenic cytokines, including fibro-
blast growth factor, vascular endothelial growth factor (VEGF), 
platelet-derived growth factor, and epidermal growth factor 
(9, 10), stimulate endothelial cells or precursors to proliferate 
and migrate, leading rapidly to new capillaries and blood vessel 
networks.
The tubule formation assay (TFA) provides an informative, 
convenient, rapid, and quantifiable approach to investigate 
angiogenesis (12). The TFA involves endothelial cell adhesion, 
migration, proteolysis, and tubule formation by the endothelial 
cells, which is initiated following seeding of the cells onto 
gelled basement matrix, the natural substrate of endothelial cell 
progenitors. The endothelial cells form capillary-like structures 
with a lumen (12). Recombinant Ov-GRN-1 (rOv-GRN-1) 
induces angiogenesis (blood vessel growth) in quail embryos in 
the chorioallantoic membrane (CAM) assay (2). However, the 
angiogenic potential of liver fluke granulin on human cells has 
not been determined. Herein, we report potent angiogenic and 
mitogenic activity of Ov-GRN-1 at nanomolar concentration 
on primary human umbilical vein endothelial cells (HUVECs) 
using both a high-throughput TFA with automated ImageJ-based 
analyses and with the xCELLigence system real-time cell assay.
MaTerials anD MeThODs
Ov-grn-1 recombinant Production
Purification of rOv-GRN-1 was achieved using an AKTA10 
purification system at 4°C (GE Healthcare) as previously 
described (2, 13). Briefly, BL21 E. coli bacterial pellet containing 
the rOv-GRN-1 expression plasmid was lysed with three freeze/
thaw cycles followed by sonication. The resulting insoluble pellet 
was solubilized in urea-containing nickel binding buffer [8  M 
urea/300 mM NaCl/50 mM imidazole/50 mM sodium phosphate 
pH 8 (Sigma)]. The 0.22-µM-filtered supernatant was passed over 
2 ×  5  ml Histrap IMAC nickel columns (GE Healthcare) and 
washed with increasing imidazole concentrations and eluted with 
500-mM imidazole in binding buffer. Refolding of urea-denatured 
rOv-GRN-1 was performed with 28 ml of G10 Sephadex resin on 
a XK16/20 column (GE Healthcare) with 7 ml applied at 100 µg/
ml and eluted with 150-mM NaCl, 50-mM sodium phosphate, pH 
6. A 120-ml Superdex 30 XK16/60 column (GE Healthcare) was 
used to fractionate rOv-GRN-1 monomer eluting at a folded size 
equivalent to ~1 kDa. Protein concentration was determined by 
a combination of microplate Bradford assay (Bio-Rad) according 
to the manufacturer’s instructions and optical density at 280 nm.
human Umbilical Vein endothelial cells
Human umbilical vein endothelial cells pooled from donors 
(PromoCell, Heidelberg, Germany) were cultured in T75 tissue 
culture flasks in complete EGM-2 medium (PromoCell) at 37°C in 
a humidified atmosphere in 5% CO2 in air. HUVECs were grown 
to ~80% confluence, after which the culture was trypsinized using 
the PromoCell Detach Kit (PromoCell). The cells investigated by 
tubule formation assay (TFA) were used from the third, fourth, 
or fifth passage only, with HUVEC passaged to ~80% confluence 
within 24 h of the TFA, as described (14).
Proliferation xcelligence assay
Cells were seeded at 5,000 cells per well in 200  µl of complete 
media (above) in E-plates (ACEA Biosciences, San Diego, CA, 
USA) and grown overnight while monitored with an xCELLi-
gence DP system (ACEA Biosciences) which monitors cellular 
events in real time by measuring electrical impedance across 
interdigitated gold micro-electrodes integrated on the bottom of 
tissue culture plates. Cells were washed three times with PBS and 
FigUre 1 | Cell proliferation induction by Ov-GRN-1 with human umbilical 
vein endothelial cells (HUVECs). (a) Normalized cell index (nCI) output of the 
xCELLigence system of treatments of 5–20 nM Ov-GRN-1 on HUVECs cells 
over 70 h. (B) nCI relative to medium only negative controls (0 nM Ov-GRN-1) 
from (a) is plotted to highlight the first 24 h after treatment. RM two-way 
ANOVA with Holm–Sidak’s multiple comparison test of Ov-GRN-1 treatment 
vs medium only control at each time point: ns = not significant; *P < 0.05; 
**P < 0.01; ***P < 0.001; ****P < 0.0001. Data points are average values of 
four biological replicates and have been nudged ±0.2–1 h to ensure that SE 
bars are visible.
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replaced with 180 µl EGM-2 basal media (no growth factors or 
supplements) and incubated for a minimum of 6 h before further 
treatment. Treatments were prepared at 10 × concentrations and 
added to each well in a total volume of 20 µl. The xCELLigence 
DP recorded cell index readings every 15  min for 3  days after 
treatment. Cell index readings were normalized before treatment 
and cell proliferation ratios were determined from four biological 
replicates and represent the relative numbers of cells compared 
to control cells. A two-way ANOVA with Holm–Sidak’s multiple 
comparisons test was used to compare Ov-GRN-1 treatment to 
medium-alone control, with P ≤ 0.05 deemed significant.
Tubule Formation assay (TFa)
Growth factor-reduced Matrigel (Corning, Corning, NY, USA) 
was plated into a 96-well μ-angiogenesis plate (ibidi, Planegg, 
Germany) at 10 μl/well, and incubated at 37°C in 5% CO2 in air 
for 60 min as described (14). HUVECs were detached (above) 
and resuspended in complete endothelial cell growth medium 
2 (EGM-2) (PromoCell), and seeded at 10,000 cells/well in 
medium supplemented with 10 µM sulforaphane (SFPH, Sigma) 
(negative control), 1.2 nM VEGF-165 (Novus Biologicals) (posi-
tive control), or 5, 10, 20, and 40 nM Ov-GRN-1. The ibidi plate 
was incubated for 12 h in a humidified atmosphere of 5% CO2 
in air at 37°C in a microscope stage top incubator (OKOLAB, 
Pozzuoli, Naples, Italy). At intervals, photomicrographs of cells 
and nascent and developed tubules were collected using a Leica 
DMi8 automated platform microscope under bright field at 
2.5 × magnification, and Leica LASX software (Leica).
analysis of Tubule Formation
Automated angiogenesis assessment was performed on TFA 
4902 pixel images by ImageJ (NIH) with the phase-contrast 
Angiogenesis Analyzer plugin tool as described (12, 15). Settings 
used were as follows: 10 pixel minimum object size; 25 pixel mini-
mum branch size; 2,500 pixel artifactual loop size; 25 pixel isolated 
element size threshold; 30 pixel master segment size threshold; 
with iteration number of 3. The four output metrics (mesh count, 
segment count, segment length, and junction count) were either 
plotted directly or as a percentage relative to the medium-alone 
blank treatment (treatment measure divided by medium-alone 
measure). A two-way ANOVA with Holm–Sidak’s multiple com-
parisons test was used to compare Ov-GRN-1 treatment against 
medium-alone blank control for the four metrics with P ≤ 0.05 
deemed significant.
Combining the four metrics into a single evenly weighted vari-
able was accomplished through the calculation of Z standardized 
scores that were based on population values (16). The formula 
below generates the Z score and represented the distance between 
the raw score and the population mean in units of the SD. 
Population values were estimated from 39 treatment replicates.
 
Z = −( )treatment metric value metric population mean
/population standard deviation  
The combined robust Z score (Z*) was generated for each 
replicate from the median Z score of the four metrics. Z* scores 
were plotted and Ov-GRN-1 treatments compared to medium-
alone blank control using one-way ANOVA with Holm–Sidak’s 
multiple comparisons test, P ≤ 0.05 was considered to be statisti-
cally significant.
resUlTs
To assess the influence of Ov-GRN-1 on HUVEC compared 
with other cell types, we analyzed HUVEC cellular proliferation 
and migration with the xCELLigence system. Treatment with 
Ov-GRN-1 induces proliferation in a range of cell types (2, 4, 17). 
Exposure of HUVEC to 5–20 nM Ov-GRN-1 showed a similar 
response (Figure 1). As the angiogenic assay with HUVECs would 
be assessed at 12 h, for proliferation, we focused on the first 24 h 
and noted minor (5–11%) non-significant increase above values 
FigUre 2 | Angiogenic screening with primary human umbilical vein endothelial cells. Cells are seeded and treatments applied at time zero. Images are taken at 
12 h and assessed in ImageJ for angiogenic properties. (a) Representative images depict the control treatments at 50× magnification: medium only; anti-angiogenic 
negative control [10 µM sulfurophane (SFPH)]; pro-angiogenic positive control [1.2 nM vascular endothelial growth factor (VEGF)]. The VEGF zoom overlay shows 
the boxed VEGF section magnified with angiogenic features overlaid: A mesh (blue) is bordered by four tubule segments (red dotted lines) that join at four branching 
junctions (green circles). (B) Representative images of 5–40 nM Ov-GRN-1 treatments at 50× magnification. (c) Automated mesh count quantitation of control and 
Ov-GRN-1 treatments represent network complexity. The mean is marked as a horizontal bar with SE bars from 3 to 9 biological replicates plotted as circles.
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of negative controls from 5 to 10  nM Ov-GRN-1 (Figure  1B). 
Twenty nanomolars were sufficient to induce a significant 14% 
increase in cell index from 4 h (*P <  0.05) that had expanded 
to 29% by 24  h (****P  <  0.0001), indicative of proliferation 
(Figure 1B). Cell migration has also been reported with bile duct 
cells from Ov-GRN-1 treatment (2, 3). In contrast to induction 
of proliferation, our HUVEC tests with 10–100 nM Ov-GRN-1 
using CIM e-plates (cell invasion and migration xCELLigence 
plates) did not reveal an increase in migration compared to 
controls (data not shown).
The TFA angiogenesis was used to assess the ability of rOv-
GRN-1 to induce capillary-like tubule structures from endothe-
lial cells. The three main characteristics considered for angiogenic 
stimulation in the TFA are highlighted in Figure  2A—tubule 
“segments” branch at “junctions” and combine to enclose a 
“mesh.” Ten (10) micromolar SFPH negative control revealed an 
ablated tubule network, as reported in other studies (18), whereas 
positive control VEGF at 1.2 nM strongly stimulated a network 
of tubules compared to the medium only group (19) (Figure 2A).
The automated ImageJ angiogenesis plugin analysis measures 
both topological features that represent network complexity 
(meshes and branching junction points) and morphometric 
descriptors that are dimensional and considered the principal 
angiogenic in  vitro response (tubule segment number and 
total tubule segment length) (8). Ov-GRN-1 treatments show 
a concentration dependent increasingly complex tubule mesh 
network (Figure  2). The mesh count raw data (Figure  2C) 
show that 40 nM Ov-GRN-1 increased the mesh count from the 
medium only control of 9.7–15.7 meshes—a highly significant 
(P <  0.0001) relative increase over the blank control of 62% 
(Figure 3A). In addition, 10 and 20 nM Ov-GRN-1 increased the 
mesh count to a lesser degree—35% increase (P <  0.01) and a 
20% increase (non-significant), respectively. While the number 
of branching junctions (Figure 3B) increased slightly (13–18%) 
with 10–40  nM Ov-GRN-1 treatments, none of these changes 
were significantly different to the medium only control. The 
dimensional measures both showed slight increases of 8–18% 
with 10–20  nM but only significant increases from 40  nM 
Ov-GRN-1 treatment (Figures  3C,D). The number of tubule 
segments increased by 31% (P < 0.01) and the associated total 
length of the tubule segments increased by 27% (P < 0.05) to the 
medium only control. The 5 nM Ov-GRN-1 treatment showed 
almost no difference (non-significant minor reductions of 5–8%) 
for all four metrics relative to medium only controls.
To assess the angiogenic potential of Ov-GRN-1 treatments 
the four metrics were converted to Z-scores and combined into 
a single median robust Z score (Z*) for each replicate (Figure 4). 
The Z* score incorporates differences from the total population 
mean and population variation. This dimensionless variable is 
a useful equally weighted mechanism to combine metrics with 
different means and variations into a single composite variable for 
statistical comparisons. Comparing the Z* scores to the medium 
only controls (Figure 4) showed 10–40 nM Ov-GRN-1 induced 
increased angiogenesis but only 10 and 40 nM showed significant 
increases (P < 0.05 and P < 0.001, respectively). As noted with 
the four separate metrics, 5  nM Ov-GRN-1 did not stimulate 
angiogenesis.
DiscUssiOn
Angiogenesis describes the growth of new vasculature and is a 
process that has been the subject of significant historical interest 
due to its involvement in a spectrum of diseases (10, 20, 21). During 
development new blood vessels are essential and angiogenesis is 
rapid (9, 10). In the fully developed adult, as part of physiologic 
processes such as wound healing, angiogenesis is turned on, but 
only transiently (9, 10). Over a century ago, studies demonstrated 
that the mechanisms of tumor growth and spread are intimately 
linked to the formation of new blood vessels from pre-existing 
larger blood vessels (10). Subsequently, it was determined that 
as this process occurs, the “angiogenic switch” is almost always 
activated and remains on, causing normally quiescent vasculature 
to sustain expanding neoplastic growths (9).
Molecular angiogenic studies have focused on VEGF, as many 
angiogenic factors induce signals that result in blood vessel sign-
aling that ultimately rely on VEGF (10, 21, 22). Recent reports focus 
FigUre 3 | Angiogenic metrics from Ov-GRN-1 treatments. ImageJ was used to quantify 12-h time point images for various characteristics of the tubule networks. 
Treatments consist of the blank control (medium only); anti-angiogenic negative control [10 µM sulforaphane (SFPH)]; pro-angiogenic positive control [1.2 nM 
vascular endothelial growth factor (VEGF)]; and 5–40 nM Ov-GRN-1 treatments and are plotted relative to the blank (medium only) control treatment. (a) Topological 
features representing an increase in complexity of the tubule network are measured by the relative number of meshes and (B) branching junctions. (c) Dimensional 
descriptors of the networked tubules include the number of tubule segments and (D) the total combined length of the tubule segments. All panels: two-way ANOVA 
with Holm–Sidak’s multiple comparisons test to compare Ov-GRN-1 treatment to medium only blank control: ns = not significant; *P < 0.05; **P < 0.01; 
****P < 0.0001. The mean is marked as a horizontal bar with SE bars from 3 to 9 biological replicates plotted as circles. Dotted line crosses the medium only blank 
100% value.
FigUre 4 | Angiogenic induction from Ov-GRN-1 treatments. Converting 
the four angiogenic metrics (meshes, junctions, segments, and segment 
length) to dimensionless Z-scores allows a pooled median value for each 
replicate (Z* score) to be generated. This enables the total angiogenic effect 
to be compared between groups. One-way ANOVA with Holm–Sidak’s 
multiple comparisons test to compare Ov-GRN-1 treatment to medium only 
blank control: ns = not significant; *P < 0.05; **P < 0.01; ***P < 0.001. The 
mean is marked as a horizontal bar with SE bars from 3 to 9 biological 
replicates plotted as circles. Dotted line crosses the medium only blank 
−0.28 Z* score.
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on angiogenic signaling via VEGF-independent mechanisms 
and associated problems with VEGF inhibitors for cancer treat-
ments (23–26). One such alternate pathway that is not blocked by 
VEGF inhibitors is driven by human progranulin, a growth factor 
comprised of 7.5 granulin active domains (24, 27). The individual 
human granulin units are difficult to produce actively (28) but 
Ov-GRN-1 is produced by liver flukes as a single unit, and is 
bioactive when purified from denatured bacterial recombinant 
expression systems and refolded (17). Previously, we have shown 
that Ov-GRN-1 is a potent growth factor that stimulates human 
cell proliferation, migration, avian angiogenesis, and ultimately 
mouse wound healing (3, 4, 7, 17). Ongoing research suggests 
the potential for beneficial therapies emanating from pathophysi-
ological investigation of granulins, including anti-tumor action 
and promotion of wound healing (7, 29, 30).
The avian CAM assay is an informative in  vivo model of 
angiogenesis (31). The CAM assay is based around blood vessel 
induction in avian embryos and results may not traverse phylo-
genetic boundaries and apply to mammalian systems. With this 
consideration ensuring the parasite growth factor Ov-GRN-1 
stimulated human angiogenesis is a useful step toward developing 
therapeutics (2, 7, 10, 32). Herein, we focused on angiogenesis 
screening using HUVEC and the tubule formation assay (TFA) 
with automated imaging in real time (14). The TFA involves a 
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range of the angiogenic processes that includes endothelial cell 
adhesion, migration, protease activity, and tubule formation (14). 
The advantages of the TFA to study angiogenesis are the ease of 
set up, short culture period, the ability to produce quantitative 
data, and its ease of adaptation toward high-throughput analysis. 
The automated TFA analysis allows comparison of both topologi-
cal features that represent network complexity and morphomet-
ric dimensional descriptors that are considered the principal 
angiogenic in vitro response (8). This depth of analysis combined 
with the high-throughput capability allows a greater range of 
treatments to be tested than the labor-intensive and subjectively 
scored CAM assay.
Human liver epithelial cells (H69 bile duct cell line) 
hyper-proliferates at Ov-GRN-1 concentrations of 12  nM and 
above (7). Although the cell types were different, we note that 
Ov-GRN-1 is able to stimulate significant HUVEC proliferation 
and angiogenic stimulation at similar concentrations of at least 
20 nM and 10 nM, respectively (Figures 1 and 4). Sample limita-
tions restricted the Ov-GRN-1 TFA maximum concentration to 
40 nM, but as the trend appeared to be dose dependent we predict 
that higher concentration would induce further angiogenesis, 
and plan to assess in the future. Mesh counts showed the most 
marked rise with a 62% highly significant increase (P < 0.0001) 
with 40 nM Ov-GRN-1, whereas the junction counts trended up 
(13–18%) but did not reach statistical significance (Figure  3). 
Whether the outcome related to the Ov-GRN-1 mechanism is 
not clear, but these phenomena may be an artifact of the TFA 
mechanics. A junction is the end point of at least three segments, 
and more may radiate from the connecting junction. Increased 
junction branching was evident with 40 nM Ov-GRN-1, a small 
increase in junctions (18%) but about double the increase in 
tubule segments (31%) was observed. The increase in segments 
can in turn enhance the mesh count, as a single segment tubule 
can grow across a mesh and split it into two smaller meshes; 
our estimated mesh numbers increased 62%. To explore this 
junction/mesh outcome further and delve into the angiogenic 
activity of Ov-GRN-1, we plan to test other aspects of angio-
genesis, including apoptosis, and to employ three-dimensional 
cell culture systems that more closely reflect the in vivo situation 
(19, 33). Furthermore, future studies will explore the Ov-GRN-1 
proliferative and signaling responses of HUVECs to compare with 
our previous work (2) that showed the transcriptional responses 
of Ov-GRN-1 treatment on the H69 bile duct cell line. The most 
relevant to Ov-GRN-1 transcriptional response to angiogenesis 
we observed in the H69 cells was the stimulation of CXCL1, 2, 5, 
and 8—chemokines that signal through CXCR2, a receptor with 
complex signaling interactions but often resulting in angiogenesis 
among other outcomes such as inflammation (22, 34).
Whereas the origin of helminth and host cell communication 
is unknown, the process likely evolved to facilitate parasitism 
(35). Metabolites participating in communication signaling may, 
however, contribute to carcinogenesis (1, 35). The close homo-
logy between liver fluke and human granulins may enable secreted 
Ov-GRN-1 to activate signaling pathways that promote angio-
genesis and wound repair of bile ducts damaged by the activities 
of the parasite (4). The stimulation of wound healing potentially 
evolved for successful parasitism and a concomitant productive 
host–parasite relationship (2, 7). Other helminth parasites release 
mediators that promote angiogenesis, and from an evolutionary 
perspective, Opisthorchis-induced neovascularization may be 
beneficial to parasitism (35, 36). However, given that angiogen-
esis represents a hallmark of cancer, the angiogenic potency of 
Ov-GRN-1 may also contribute to liver fluke infection-induced 
malignancy (2, 30, 35).
The current findings confirmed potent angiogenic signaling 
of liver fluke with nanomolar levels of granulin and expand upon 
previous reports using an in  vivo CAM assay (2). Liver fluke 
granulin likely contributes to the carcinogenicity of liver fluke 
infection in the human biliary tract (2, 35, 36). On the other hand, 
it also holds marked potential as a therapeutic wound-healing 
agent and as a vaccine against the liver fluke infection-induced 
cancer (2, 7, 35).
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